Cartesian Therapeutics Operating Income

Cartesian Therapeutics (RNAC) currently reports a operating income of $-78M as of June 2026. That compares with $-88M in the prior-year period — up 11.8% year over year. Use the charts on this page to explore Cartesian Therapeutics's operating income history and peer comparisons.

Cartesian Therapeutics's operating income increased from $-88M to $-78M — a 11.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cartesian Therapeutics reported $-78M in operating income as of June 2026. That compares with $-88M in the prior-year period — up 11.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-78M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cartesian Therapeutics, and consider following RNAC for alerts when major investors trade the stock.

Cartesian Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-78M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNAC with unrelated industries.